Cadrenal Therapeutics, Inc. Capital Expenditures
Cadrenal Therapeutics, Inc. (CVKD) reported Capital Expenditures of $5.10 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $1.85K.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $0.00.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $3.25K.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $5.10K, a 21.92% decline from fiscal 2024.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $6.54K, a 100.89% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.25K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 8 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 11 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.85K derived: sum of 2 quarters · filed 2026-03-31 | $1.85K derived: sum of 3 quarters · filed 2026-08-13 | $5.10K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $1.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.85K derived: sum of 2 quarters · filed 2026-08-13 | $5.10K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.25K 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $3.25K 10-Q · filed 2026-05-07 | |||||
| 2024-12-31 | $6.54K 10-K · filed 2026-03-31 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.00 derived: sum of 2 quarters · filed 2025-03-13 | $3.25K 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.25K 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $3.25K 10-Q · filed 2024-08-07 | |||||
| 2022-12-31 | $2.28K 10-K · filed 2024-03-11 | |||||
| 2022-09-30 | $2.28K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |